GENB Generate Biomedicines, Inc. Common Stock
XNAS
12.36
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
GENB
$12.36
—
Key stats
$12.36
Pre-market
$12.55
+1.62%
- 52-Week Range
- $11.00 – $22.67
- YTD
- -2.33%
- Straddle Price
- $3.85
- P/C Vol Ratio
- 2.00
- Market Cap
- $1.6B
- Open
- $12.52
- Day Range
- $12.20 – $12.59
- Volume
- 340,898
- Prev Close
- $12.41
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 0.79 |
| Cost of Equity (CAPM) | 9.09% (VRP-adj) |
| WACC | 8.95% |
| Volatility Risk Premium | +90.3pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Quality Score | 0/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $15.18 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $13.50 |
| Bollinger Width / SMA20 | 203.6% (drives anchor stability) |
| Net Debt | $0.0B |
Peers used for multiples: BEAM, CDNA, CRSP, GH, LLY, NTRA, TWST, VCYT
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 32.3× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 29.0× · 3 peers |
| Peer P/B | n/a | 0% | median 8.4× · 7 peers |
| Peer P/S | n/a | 0% | median 17.4× · 8 peers |
| Market Anchor (SMA50) | $15.18 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $13.07 | 0% | 7 strikes · skew +0.09 |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $1.6B
- List Date
- 2026-02-27
- CIK
- 0002100782
- Next Earnings
- 2026-11-05
- EPS Forecast
- ($0.50) (3 est.)
- Headquarters
- Somerville, MA
- Homepage
- https://www.generatebiomedicines.com
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug di…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | 0.00% | 0.00% |
| Mar | 2.71% | 2.71% |
| Apr | -5.11% | -5.11% |
| May | -0.23% | -0.23% |
| Jun | 30.07% | 30.07% |
| Jul | -15.41% | -15.41% |
| Aug | 6.49% | 6.49% |
| Sep | -4.88% | -4.88% |
| Oct | -10.51%* | -10.51% |
| Nov | -- | -- |
| Dec | -- | -- |
| Total | -3.02% | -3.02% |
* Only 1 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $13.37
SMA 50: $15.12
SMA 200: —
Current: $12.35
EMA 12: $12.94
EMA 26: $13.71
MACD: -0.7605 | Signal: -0.0208
BEARISH
ADX (14): 25.55
TREND
+DI: 14.20
−DI: 28.12
Momentum Oscillators
RSI (14): 38.24
NEUTRAL
Stoch %K: 22.44
Stoch %D: 29.68
Williams %R: -83.08
Volume & Volatility
BB Upper: $15.17
BB Lower: $11.57
NEUTRAL
OBV: 9,206,508
Vol SMA 20: 883,660
Vol ROC: -49.59%
ATR: $0.85
True Range: $0.39
HV 20: 70.7%
HV 30: 68.2%
HV 60: 83.0%
Data Summary
Data Points: 167
Last Updated:
Date Range: 2026-02-27T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All GENB news →
GENB Options Activity & IV Rank
Volatility Metrics
Current IV: 77.3%
7-DTE IV: —
Expected Move: $3.85
7-DTE Move: $3.85
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 5
Put Volume: 10
P/C Volume: 2.0
BEARISH
Call OI: 1,505
Put OI: 59
P/C OI: 0.039
Total OI: 1,564
ATM Options Pricing
ATM Call: $1.00
ATM Put: $2.85
Call %: 8.1%
Put %: 23.1%
Chain Summary
Chain Volume: 177
Chain OI: 2,070
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Not enough history yet to rank today's net dealer gamma against this name's own record.
Gamma percentile
—
vs own history
GEX tilt
+0.96
OI-weighted, today
Vanna tilt
+1.00
δ-sensitivity to IV
Charm tilt
-1.00
δ-decay vs time
Vanna tilt +1.00: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -1.00: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 149.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$3.85Oct 26
Beta Analysis
Risk Metrics
Beta: 1.3919
Alpha: 8.22%
Correlation: 0.2182
R-Squared: 4.8%
Stock Volatility: 84.4%
Market Volatility: 13.2%
Analysis Details
Benchmark: SPY
Data Points: 166
Period: 252 trading days
Data Points: 166
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own GENB
2 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $669K | #2491 of 3138 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $370K | #3280 of 3716 | -94.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
GENB Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
GENB Insider Trading (Form 4)
Latest: 2026-09-03Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Frances Arnold | Director | Sell (S) | −1,000 | $16.00 | -$16.0K | EDGAR |
| 2026-03-06 | Michael Nally | Chief Executive Officer | Buy (P) | +20,000 | $12.00 | $240.0K | EDGAR |
| 2026-03-02 | Beth Grous | Chief People Officer | Buy (P) | +300 | $16.00 | $4.8K | EDGAR |
| 2026-03-02 | Paul Gray Parker | Director | Grant (A) | +29,561 opt | — | EDGAR | |
| 2026-03-02 | Nancy A Simonian | Director | Grant (A) | +29,561 opt | — | EDGAR | |
| 2026-03-02 | Frances Arnold | Director | Grant (A) | +29,561 opt | — | EDGAR | |
| 2026-03-02 | Marsha Fanucci | Director | Grant (A) | +29,561 opt | — | EDGAR | |
| 2026-03-02 | Rupert Vessey | Director | Grant (A) | +29,561 opt | — | EDGAR | |
| 2026-03-02 | Laurie Anne Lee | Chief Medical Officer | Grant (A) | +42,230 opt | — | EDGAR | |
| 2026-03-02 | Jane L Mendillo | Director | Buy (P) | +1,500 | $16.00 | $24.0K | EDGAR |
| 2026-03-02 | Jason Silvers | President & CFO | Buy (P) | +1,500 | $16.00 | $24.0K | EDGAR |
| 2026-03-02 | Stephane Bancel | Director | Conv (C) | +724,160 | — | EDGAR | |
| 2026-03-02 | Sean Martin | Chief Legal Officer & GC | Grant (A) | +190,034 opt | — | EDGAR | |
| 2026-03-02 | Michael Nally | Chief Executive Officer | Conv (C) | +658,327 | — | EDGAR | |
| 2026-03-02 | Gevorg Grigoryan | Chief Technology Officer | Grant (A) | +491,976 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
GENB Insider Holdings
8 insiders · @ $12.35
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | FPN General Partner LLC | 10%+ Owner | 4,340,252 | $53.60M | $600.00M | 1 | 2026-03-02 |
| 2 | Flagship Pioneering Fund VI, L.P. | 10%+ Owner | 2,777,752 | $34.31M | $525.00M | 1 | 2026-03-02 |
| 3 | Michael Nally | Chief Executive Officer | 1,889,361 | $23.33M | $240.0K | 2 | 2026-03-06 |
| 4 | Stephane Bancel | Director | 1,184,989 | $14.63M | $0 | 1 | 2026-03-02 |
| 5 | Frances Arnold | Director | 463,944 | $5.73M | -$16.0K | 2 | 2026-09-03 |
| 6 | Jane L Mendillo | Director | 1,500 | $18.5K | $24.0K | 1 | 2026-03-02 |
| 7 | Jason Silvers | President & CFO | 1,000 | $12.3K | $24.0K | 1 | 2026-03-02 |
| 8 | Beth Grous | Chief People Officer | 300 | $3.7K | $4.8K | 1 | 2026-03-02 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
GENB Board & Officers
As of SEC filings through Sep 3, 2026Directors 9
- Frances Arnold · since Feb 26, 2026
- Jane L Mendillo · since Feb 26, 2026
- Marsha Fanucci · since Feb 26, 2026
- Michael Nally · since Feb 26, 2026
- Nancy A Simonian · since Feb 26, 2026
- Noubar Afeyan · since Feb 26, 2026
- Paul Gray Parker · since Feb 26, 2026
- Rupert Vessey · since Feb 26, 2026
- Stephane Bancel · since Feb 26, 2026
Officers 7
- Michael Nally · Chief Executive Officer · since Feb 26, 2026
- Jason Silvers · President & CFO · since Feb 26, 2026
- Aarif Khakoo · Chief Scientific Officer · since Feb 26, 2026
- Beth Grous · Chief People Officer · since Feb 26, 2026
- Gevorg Grigoryan · Chief Technology Officer · since Feb 26, 2026
- Laurie Anne Lee · Chief Medical Officer · since Feb 26, 2026
- Sean Martin · Chief Legal Officer & GC · since Feb 26, 2026
10% owners 15
- FPN General Partner LLC (entity) · since Feb 26, 2026
- Flagship Pioneering Fund VI General Partner LLC (entity) · since Feb 26, 2026
- Flagship Pioneering Fund VI, L.P. (entity) · since Feb 26, 2026
- Flagship Pioneering Fund VII General Partner LLC (entity) · since Feb 26, 2026
- Flagship Pioneering Fund VII, L.P. (entity) · since Feb 26, 2026
- Flagship Pioneering Special Opportunities Fund II General Partner LLC (entity) · since Feb 26, 2026
- Flagship Pioneering Special Opportunities Fund II, L.P. (entity) · since Feb 26, 2026
- Flagship Pioneering, LLC (entity) · since Feb 26, 2026
- Flagship VentureLabs VI LLC (entity) · since Feb 26, 2026
- Flagship VentureLabs VI Manager LLC (entity) · since Feb 26, 2026
- Fpn II, L.p. (entity) · since Feb 26, 2026
- Noubar Afeyan · since Feb 26, 2026
- Nutritional Health LTP Fund General Partner LLC (entity) · since Feb 26, 2026
- Nutritional Health LTP Fund, L.P. (entity) · since Feb 26, 2026
- Pioneering Medicines 02, LLC (entity) · since Mar 2, 2026
Changes in the last 10 years (31)
| Mar 2, 2026 | Pioneering Medicines 02, LLC became a 10% owner |
| Feb 26, 2026 | Stephane Bancel became a director |
| Feb 26, 2026 | Sean Martin became Chief Legal Officer & GC |
| Feb 26, 2026 | Rupert Vessey became a director |
| Feb 26, 2026 | Paul Gray Parker became a director |
| Feb 26, 2026 | Nutritional Health LTP Fund, L.P. became a 10% owner |
| Feb 26, 2026 | Nutritional Health LTP Fund General Partner LLC became a 10% owner |
| Feb 26, 2026 | Noubar Afeyan became a director |
| Feb 26, 2026 | Noubar Afeyan became a 10% owner |
| Feb 26, 2026 | Nancy A Simonian became a director |
| Feb 26, 2026 | Michael Nally became a director |
| Feb 26, 2026 | Michael Nally became Chief Executive Officer |
| Feb 26, 2026 | Marsha Fanucci became a director |
| Feb 26, 2026 | Laurie Anne Lee became Chief Medical Officer |
| Feb 26, 2026 | Jason Silvers became President & CFO |
| Feb 26, 2026 | Jane L Mendillo became a director |
| Feb 26, 2026 | Gevorg Grigoryan became Chief Technology Officer |
| Feb 26, 2026 | Frances Arnold became a director |
| Feb 26, 2026 | Fpn II, L.p. became a 10% owner |
| Feb 26, 2026 | Flagship VentureLabs VI Manager LLC became a 10% owner |
| Feb 26, 2026 | Flagship VentureLabs VI LLC became a 10% owner |
| Feb 26, 2026 | Flagship Pioneering, LLC became a 10% owner |
| Feb 26, 2026 | Flagship Pioneering Special Opportunities Fund II, L.P. became a 10% owner |
| Feb 26, 2026 | Flagship Pioneering Special Opportunities Fund II General Partner LLC became a 10% owner |
| Feb 26, 2026 | Flagship Pioneering Fund VII, L.P. became a 10% owner |
| Feb 26, 2026 | Flagship Pioneering Fund VII General Partner LLC became a 10% owner |
| Feb 26, 2026 | Flagship Pioneering Fund VI, L.P. became a 10% owner |
| Feb 26, 2026 | Flagship Pioneering Fund VI General Partner LLC became a 10% owner |
| Feb 26, 2026 | FPN General Partner LLC became a 10% owner |
| Feb 26, 2026 | Beth Grous became Chief People Officer |
| Feb 26, 2026 | Aarif Khakoo became Chief Scientific Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
GENB Proposed Insider Sales (Form 144)
Latest: 2026-09-01
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $16K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
ARNOLD FRANCES (1, $16K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-01 | ARNOLD FRANCES | Director | 1,000 | $16.0K | 2026-09-01 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
23 ETFs hold GENB
23 shown · $50.49M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $28.4M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $7.7M | $74.6B | 2026-10-23 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $4.2M | — | 2026-09-30 |
| 4 | JTEK JPMorgan U.S. Tech Leaders ETF | JPMorgan | 0.08% | $3.6M | $4.6B | 2026-10-23 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.1M | — | 2026-09-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.01% | $2.0M | $13.7B | 2026-10-23 |
| 7 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $814,555 | $13.9B | 2026-10-23 |
| 8 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.00% | $526,854 | $10.7B | 2026-10-23 |
| 9 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.76% | $351,484 | — | 2026-07-31 |
| 10 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.02% | $282,256 | — | 2026-09-30 |
| 11 | AVUS Avantis U.S. Equity ETF | Avantis | 0.00% | $172,561 | $14.7B | 2026-10-23 |
| 12 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $146,372 | — | 2026-10-26 |
| 13 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $104,659 | — | 2026-09-30 |
| 14 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $31,212 | — | 2026-09-30 |
| 15 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $17,241 | — | 2026-10-26 |
| 16 | ISCB iShares Morningstar Small-Cap ETF | Nport | 0.01% | $15,610 | — | 2026-07-31 |
| 17 | URTY ProShares UltraPro Russell2000 | ProShares | 0.00% | $13,214 | — | 2026-10-26 |
| 18 | UWM ProShares Ultra Russell2000 | ProShares | 0.00% | $9,262 | — | 2026-10-26 |
| 19 | GNMX Corgi Genomics & Precision Medicine ETF | Corgi | 0.56% | $7,262 | $1.3M | 2026-10-26 |
| 20 | RESM Columbia Research Enhanced Small Cap ETF | Nport | 0.03% | $1,080 | — | 2026-06-30 |
| 21 | HDG ProShares Hedge Replication ETF | ProShares | 0.00% | $370 | — | 2026-10-26 |
| 22 | RB ProShares Russell 2000 Dynamic Buffer ETF | ProShares | 0.01% | $99 | — | 2026-10-26 |
| 23 | ARKG ARK Genomic Revolution ETF | ARK Invest | 0.97% | — | — | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.42M
SI % of Float
12.81%
Days to Cover
5.75
Short Vol Ratio
61.1%
Free Float
57.89M
Float %
45.1%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14